Condensed Interim Consolidated Financial Statements
For the three and nine months ended September 30, 2017 and 2016
(Unaudited)

Table of Contents

For the three and nine months ended September 30, 2017 and 2016

	Page
Condensed Interim Consolidated Financial Statements	
Condensed Interim Consolidated Statements of Financial Position	1
Condensed Interim Consolidated Statements of Loss and Comprehensive Loss	2
Condensed Interim Consolidated Statements of Changes in Equity (Deficiency)	3
Condensed Interim Consolidated Statements of Cash Flows	4
Notes to Condensed Interim Consolidated Financial Statements	5 - 17

Notice of No Auditor Review of Condensed Interim Consolidated Financial Statements

The accompanying unaudited condensed interim consolidated financial statements of the Company have been prepared by and are the responsibility of the Company's management. The Company's independent auditor, McGovern, Hurley, Cunningham, LLP, has not performed a review of these unaudited condensed interim consolidated financial statements, in accordance with standards established by the Institute of Chartered Professional Accountants for a review of condensed interim consolidated financial statements by an entity's auditor.

BacTech Environmental Corporation November 28, 2017

Condensed Interim Consolidated Statements of Financial Position

(Unaudited, expressed in Canadian dollars, unless otherwise stated)

	As at September 30, 2017	As at December 31, 2016
	\$	<u> </u>
Assets		
Current assets	24.00	1 102
Cash	34,895	1,103
Other receivable (note 5)	21,700	24,005
Prepaid expenses	98,616	76,052
Total current assets	155,211	101,160
Total assets	155,211	101,160
Liabilities Current liabilities		
Accounts payable and accrued liabilities (notes 7 and 8)	2,041,803	1,861,442
Loan payable (note 9)	150,000	150,000
Current portion payable to Aquila Resources Inc. (note 6)	91,471	91,471
Total current liabilities	2,283,274	2,102,913
Payable to Aquila Resources Inc. (note 6)	69,823	69,823
Debentures (note 10)	505,060	-
Total liabilities	2,858,157	2,172,736
Equity (deficiency)		
Share capital (note 11)	4,756,152	4,430,282
Option reserve (note 13)	123,720	236,888
Warrant reserve (note 12)	306,780	249,672
Deficit	(7,889,598)	(6,988,418)
Total deficiency	(2.702.946)	(2,071,576)
Total liabilities and deficiency	155,211	101,160

Nature of Operations and Going Concern (note 1) Commitments and Contingencies (note 19) Subsequent events (note 21)

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Approved by the Board

Signed: "Ross Orr"

Director

Signed: "Jay Naster"

Director

Condensed Interim Consolidated Statements of Loss and Comprehensive Loss

(Unaudited, expressed in Canadian dollars, unless otherwise stated)

	Three months ended September 30		Nine months ended September 30	
	2017	2016	2017	2016
	\$	\$	\$	\$
Expenses				
Operating and administrative costs (note 15)	192,450	199,913	596,618	570,141
Finance charges (note 16)	33,833	9,210	62,520	30,380
Project Expenditures (note 20)	106,217	-	398,007	-
Net loss and comprehensive loss for the period	(332,500)	(209,123)	(1,057,145)	(600,521)
Basic and diluted loss per share (note 14)	(0.01)	(0.00)	(0.02)	(0.01)
Weighted average number of common shares				
Outstanding (note 14)	63,377,930	47,984,966	60,915,560	44,344,562

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Condensed Interim Consolidated Statements of Changes in Equity (Deficiency)

(Unaudited. expressed in Canadian dollars, unless otherwise stated)

	Share Capital	Option Reserve	Warrant Reserve	Deficit	Total Equity
	\$	\$	\$	\$	\$
Balance, December 31, 2015	4,007,574	156,668	86,372	(5,877,368)	(1,626,754)
Shares issued pursuant to private placement (note 11(i))	315,335	-	210,224	-	525,559
Expired stock options	-	(4,980)	-	4,980	-
Share based payments (note 13)	-	62,700	-	-	62,700
Share issue costs	(6,561)	-	-	-	(6,561)
Net loss for the period	-	-	-	(600,521)	(600,521)
Balance, September 30, 2016	4,316,348	214,388	296,596	(6,472,909)	(1,645,577)
Shares issued pursuant to private placement (note 11(ii))	117,924	-	7,076	-	125,000
Expired Warrants	-	-	(54,000)	54,000	-
Share based payments	-	22,500	-	-	22,500
Share issue costs	(3,990)	-	-	-	(3,990)
Net loss for the period	-	-	-	(569,509)	(569,509)
Balance, December 31, 2016	4,430,282	236,888	249,672	(6,988,418)	(2,071,576)
Shares issued pursuant to private placement (note 11(iii))	57,070	-	15,430	-	72,500
Shares issued pursuant to debenture financing (note $10(a)$)	70,100	-	350	-	70,450
Shares issued for debt (note 11(iv)	202,500	-	-	-	202,500
Warrants issued pursuant to debenture financing (<i>note</i> $10(b)$)	-	-	73,700	-	73,700
Expired Options	-	(123,593)	-	123,593	-
Share based payments	-	10,425	-	-	10,425
Expired Warrants	-	-	(32,372)	32,372	-
Share issue costs	(3,800)	-	-	-	(3,800)
Net loss for the period	-	-	-	(1,057,145)	(1,057,145)
Balance, September 30, 2017	4,756,152	123,720	306,780	(7,889,598)	(2,702,946)

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Condensed Interim Consolidated Statements of Cash Flows

(Unaudited, expressed in Canadian dollars, unless otherwise stated)

	Nine months ended September 30 2017	Nine months ended September 30 2016
	\$	\$
Cash flow from operating activities		
Cash paid to suppliers, employees and consultants	(671,508)	(350,458)
	(671,508)	(350,458)
Cash flow from financing activities		
Gross proceeds from private placements	72,500	525,559
Gross proceeds from debenture financings	645,000	-
Net repayment of loans payable	-	(60,000)
Share issue costs	(12,200)	(6,561)
	705,300	458,998
Increase in cash	33,792	108,540
Cash, beginning of period	1,103	7,650
Cash, end of period	34,895	116,190

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Notes to Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2017 and 2016

1. Nature of Operations and Going Concern

BacTech Environmental Corporation (the "Company" or "BEC") was incorporated by REBgold Corporation ("REBgold" and formerly BacTech Mining Corporation) on October 5, 2010 under the Canada Business Corporations Act. REBgold completed a divisive reorganization by way of a Plan of Arrangement whereby a newly formed subsidiary, the Company, was granted rights and interests in REBgold's existing and proposed tailings remediation projects and an exclusive, perpetual, royalty-free license to use REBgold's proprietary bioleaching technology for reclamation of historic mine tailings. REBgold retained the primary rights to the bioleaching technology. The technology utilizes bacteria to extract precious and base metals and has been traditionally used to treat difficult-to-treat sulphide ores and concentrates. During the year ended December 31, 2013, REBgold amalgamated with Aquila Resources Inc. and is hereinafter referred to as "Aquila".

The business plan for the Company is to apply bioleaching technology to abatement and reclamation projects to remove the harmful elements such as arsenic and sulphur from the environment, where this can be assisted by a positive cash flow from metal recovery. Examples of metals which could potentially be extracted include gold, silver, cobalt, nickel, copper, uranium and zinc. The Company's head office is located at 20 Eglinton Avenue West, Suite 1820, Toronto, Ontario, M4R 1K8.

The accompanying condensed interim consolidated financial statements of the Company have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.

The Company has no sources of recurring revenue, has incurred losses amounting to \$7,889,598 since its inception, has a working capital deficit of \$2,128,063 at September 30, 2017, and is dependent on financings to fund its operations. The ability of the Company to continue as a going concern is dependent upon the continuing financial support of shareholders or other investors, obtaining new financing on commercial terms acceptable to the Company to enable it to monetize its intellectual property assets, and upon attaining profitable operations once such assets can be monetized, all of which outcomes are materially uncertain and which, taken together, cast significant doubt over the ability of the Company to continue as a going concern. These condensed interim consolidated financial statements do not include any adjustments to the carrying values of the Company's assets, liabilities, and expenses and the related statement of financial position and statement of loss classifications that would be necessary if the going concern assumption were inappropriate. Such adjustments have not been quantified by management but could be material.

The Company funded its operations for the nine months ended September 30, 2017 from existing cash reserves, \$72,500 in gross proceeds from equity private placement, and \$645,000 from debenture financings. The Company does not have sufficient cash reserves to fund its administrative costs and fully fund all project development initiatives for the coming twelve month period, and to repay its liabilities to trade creditors and debt holders. Management is actively involved in identifying reclamation and abatement ventures amenable to the application of the Company's technology license, and in seeking new equity financing to enable it to service the Company's liabilities and its ongoing administrative costs. There can be no assurance that the Company will be successful in these initiatives.

Notes to Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2017 and 2016

2. Basis of Consolidation and Presentation

Statement of Compliance with International Financial Accounting Standards ("IFRS")

Statement of Compliance

These condensed interim consolidated financial statements of the Company have been prepared in accordance with International Accounting Standard 34 Interim Financial Reporting ("IAS 34") as issued by the International Accounting Standards Board ("IASB") and using the accounting policies the Company reported in Note 2 and 3 in its audited annual consolidated financial statements for the year ending December 31, 2016. These condensed interim consolidated financial statements do not include all the information required for full annual financial statements.

The accounting policies have been applied consistently to all periods presented in these condensed interim consolidated financial statements.

These condensed interim consolidated financial statements were authorized for issuance by the Board of Directors of the Company on November 28, 2017.

Basis of Preparation and Presentation

These condensed interim consolidated financial statements have been prepared on a historical cost basis except for the revaluation of certain financial instruments. In addition, these condensed interim consolidated financial statements have been prepared using the accrual basis of accounting except for cash flow information.

The condensed interim consolidated financial statements are presented in Canadian dollars, which is also the Company's functional currency.

Basis of Consolidation

These condensed interim consolidated financial statements comprise the financial statements of the Company and its subsidiaries, BacTech Manitoba Corp. and Empresa Minera Ambiental Bactech S.A. Accounting policies of the subsidiary have been changed where necessary to ensure consistency with the policies adopted by the Company.

Intercompany balances and transactions, including unrealized income and expenses arising from intercompany transactions, are eliminated in preparing the condensed interim consolidated financial statements.

3. Significant Accounting Policies

Measurement Uncertainty

The preparation of these condensed interim consolidated financial statements requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual outcomes could differ from these estimates. These condensed interim consolidated financial statements include estimates that, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the financial statements, and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the period in which the estimate is revised and future periods, if the revision affects both current and future periods. These estimates are based on historical experience, current and future economic conditions and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Notes to Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2017 and 2016

Critical Judgements and Estimation Uncertainties

The preparation of condensed interim consolidated financial statements in conformity with IFRS requires the Company's management to make judgments, estimates and assumptions about future events that affect the amounts reported in the condensed interim consolidated financial statements and related notes to the financial statements. Although these estimates are based on management's best knowledge of the amount, event or actions, actual results may differ from those estimates and these differences could be material.

The areas which require management to make significant judgments, estimates and assumptions in determining carrying values include, but are not limited to:

- Assets' carrying values and impairment charges
In the determination of carrying values and impairment charges, management looks at the higher of recoverable amount or fair value less costs to sell in the case of assets and at objective evidence, significant or prolonged decline of fair value on financial assets indicating impairment. These determinations and their individual assumptions require that management make a decision based on the best available information at each reporting period.

4. Current and Future Changes in Accounting Policies

Future Changes

Certain pronouncements were issued by the IASB or the IFRIC that are mandatory for accounting periods on or after January 1, 2017 or later periods. Many are not applicable or do not have significant impact of the Company and have been excluded. The following have not yet been adopted and are being evaluated to determine their impact on the Company.

IFRS 9 – Financial Instruments ("IFRS 9") was issued by the IASB in November 2009 with additions in October 2010 and May 2013 and will replace IAS 39 Financial Instruments: Recognition and Measurement ("IAS 39"). IFRS 9 uses a single approach to determine whether a financial asset is measured at amortized cost or fair value, replacing the multiple rules in IAS 39. The approach in IFRS 9 is based on how an entity manages its financial instruments in the context of its business model and the contractual cash flow characteristics of the financial assets. Most of the requirements in IAS 39 for classification and measurement of financial liabilities were carried forward unchanged to IFRS 9, except that an entity choosing to measure a financial liability at fair value will present the portion of any change in its fair value due to changes in the entity's own credit risk in other comprehensive income, rather than within profit or loss. The new standard also requires a single impairment method to be used, replacing the multiple impairment methods in IAS 39. IFRS 9 is effective for annual periods beginning on or after January 1, 2018. Earlier adoption is permitted.

5. Other Receivables

Other receivables consist of the following:

-	September 30	December 31
	2017	2016
	\$	\$
Sales tax receivable	21,700	15,955
Other receivable	-	8,050
Total other receivables	21,700	24,005

Notes to Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2017 and 2016

6. Payable to Aquila Resources Inc.

	September 30 2017	December 31 2016
	\$	\$
Plan of Arrangement loan	69,823	69,823
Net accruals/receivables	9,471	9,471
Aquila Debenture payable	82,000	82,000
	161,294	161,294
Less current portion	91,471	91,471
	69,823	69,823

The balance is unsecured, non-interest bearing, and has no set terms of repayment except for the debenture payable component.

Under the Plan of Arrangement ("Arrangement") completed with Aquila, the Company assumed 20% of Aquila Resources Inc.'s ("Aquila") debenture payable obligation which consisted of 43 \$10,000 unsecured convertible debentures, initially maturing on October 13, 2011 but were extended to April 13, 2015 over a series of extension agreements, with an interest rate of 18% per year payable semi-annually. The Company is obligated to pay to Aquila the Company's principal portion to Aquila which is \$82,000 plus 20% of the interest accrued from December 2, 2010. The Debenture has reached its maturity date and Aquila has repaid the debenture obligation to the debenture holders.

7. Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities consist of the following as at:

	September 30	December 31
	2017	2016
	\$	\$
Trade payables	359,015	427,200
Accrued liabilities other	1,682,788	1,434,242
Total	2,041,803	1,861,442

Included in accrued liabilities, there are certain liabilities totaling approximately \$150,000, that due to the length of time passed since the Company recorded them, are uncollectable by the vendor and the Company will not be required to pay.

8. Related Party Transactions

Related party transactions consist of the following for the nine months ended:

	September 30	September 30
	2017	2016
	\$	\$
Salaries and management fees	213,750	213,750
Share-based compensation	-	30,800
Total	213,750	244,550

Notes to Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2017 and 2016

Included in accounts payable and accrued liabilities is \$880,695 due to related parties at September 30, 2017 (2016 - \$779,556).

9. Loan Payable

On January 20, 2015, the Company arranged for a loan from a third party. The purpose of the loan is to provide working capital for future exploration and development projects.

The terms of the loan payable are as follows; (i) Total amount available of loan is \$150,000, (ii) bonus shares of 200,000 common shares of the Company for every \$50,000 tranche, up to a total of 600,000 common shares can be issued if the full amount is drawn down, (iii) a 1% Net Profit Interest ("NPI") in a future remediation project, and (iv) earns interest at a rate of 12% per annum. The loan was due 120 days from the date of the first advance which was May 20, 2015. If the loan is not repaid at maturity or reorganized, interest will be 1.5% per month compounded. The loan has not been repaid and continues to accrue interest.

The 600,000 common shares have not been issued and the value of the shares is included in accounts payable and accrued liabilities on the condensed interim consolidated statement of financial position. The shares have been valued at \$13,000 based on the quoted market value of the common shares and forms part of finance charges for fiscal 2015.

On October 8, 2015, the Company arranged for an additional loan from another third party. The loan earned interest at 15%, was unsecured and due on demand. The purpose of the loan was to provide working capital to complete an agreement with the Bolivian Government. Total amount available of the loan was \$350,000 but only \$102,000 was advanced on the loan. The loan was repaid in full during the year ended December 31, 2016 plus the accrued interest.

10. Debentures

Debentures consist of the following as at:

	September 30	December 31
	2017	2016
	\$	\$
Debentures with Bonus Interest	377,880	_
Debentures with NSR	127,180	-
Total	505,060	-

(a) Debentures with Bonus Interest

Between April 20, 2017 to June 26, 2017, BacTech completed three tranches of a debenture financing for gross proceeds of \$445,000 and accompanied by the issuance of 1,780,000 common shares which are included as a Bonus Equity Interest. The debenture has a 2-year term and pays 12% interest annualy. The debenture included a 20% common stock bonus interest payment. For example, a \$10,000 debenture would be accompanied by \$2,000 worth of BacTech common shares priced at \$0.05 per share. This would provide the investor with 40,000 common shares subject to a 4-month restriction on resale from the date of closing.

The fair value of the bonus shares was determined by reference to the trading prices of the Company's common shares on the date the tranches were closed. The Company issued 1,780,000 common shares in connection with

Notes to Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2017 and 2016

the debenture financing with an aggregate value of \$70,100. Transaction costs included a cash commission of \$8,400 and 84,000 warrants. Each warrant entitles the holder to purchase one common share at an exercise prices of \$0.10 for a period of 12 months and valued at \$350. The aggregate transaction costs which includes the bonus shares, cash commission and warrants is recorded against the debenture and is being amortized over the life of the debenture and shown as accretion expense.

	September 30,
	2017
	\$
Face value of debentures	445,000
Transactions costs allocated to debentures	(78,850)
Accumulated accretion	11,730
	377,880

(b) Debentures with NSR

Between August 14, 2017 and September 22, 2017, BacTech completed two tranches of a debenture financing for gross proceeds of \$200,000 and accompanied by the issuance of 1,666,760 common shares purchase warrants and Net Smelter Royalty ("NSR) of 1.25% in relation to the project in Bolivia. The debenture has a 2-year term and pays 12% interest annually.

The fair value of the bonus shares was determined by reference to the fair market value of the warrants issued in connection with the debenture financing with an aggregate value of \$73,700. Each warrant entitles the holder to purchase one common share at an exercise prices of \$0.05 for a period of 5 years from date of issue. No value was placed upon the NSR at this time since the project is not in production. The aggregate value of the transaction costs which includes the warrants is recorded against the debenture and is being amortized over the life of the debenture and shown as accretion expense.

	September 30,
	2017
	\$
Face value of debentures	200,000
Transactions costs allocated to debentures	(73,700)
Accumulated accretion	880
	127,180

Notes to Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2017 and 2016

11. Share Capital

Authorized: Unlimited common shares without par value

Issued and outstanding:	Number of shares	Amount
		\$
Balance, December 31, 2015	42,393,944	4,007,574
Private placement (i)	13,138,986	328,298
Private placement (ii)	2,500,000	94,410
Balance, December 31, 2016	58,032,930	4,430,282
Private placement (iii)	1,450,000	56,570
Shares issued pursuant to the debenture financing (Note 10 (a))	1,780,000	66,800
Shares issued for debt (iv)	4,050,000	202,500
Balance, September 30, 2017	65,312,930	4,756,152

(i) Between June 8 and September 27, 2016, the Company completed four tranches of a private placement for total gross proceeds of \$525,559 and issued 13,138,986 units at \$0.04 per unit. Each unit consisted of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share of the Company at an exercise price of \$0.10 for a period of 2 years. All securities issued in connection with the offering and the underlying securities were subject to a four month hold period. The fair value of common share purchase warrants issued in this placement was estimated at \$190,700. Share issue costs incurred on this private placement amounted to \$6,561.

Related parties to the corporation participated in this transaction by purchasing 5,225,000 of the total units issued for this private placement for gross proceeds of \$209,000.

- (ii) On December 20, 2016, the Company completed the first tranche of a private placement for total gross proceeds of \$125,000 and issued 2,500,000 units at \$0.05 per unit. Each unit consisted of one common share and one half of one common share purchase warrant. Each whole warrant entitles the holder to purchase one common share of the Company at an exercise price of \$0.10 for a period of 2 years. All securities issued in connection with the offering and the underlying securities were subject to a four month hold period. The fair value of common share purchase warrants issued in this placement was estimated at \$26,600. Share issue costs incurred on this private placement amounted to \$3,990.
- (iii) On January 19, 2017 and February 21, 2017, the Company completed two more tranches of a private placement for total gross proceeds of \$72,500 and issued 1,450,000 units at \$0.05 per unit. Each unit consisted of one common share and one half of one common share purchase warrant. Each whole warrant entitles the holder to purchase one common share of the Company at an exercise price of \$0.10 for a period of 2 years. All securities issued in connection with the offering and the underlying securities were subject to a four month hold period. The fair value of common share purchase warrants issued in this placement was estimated at \$15,430. Share issue costs incurred on this private placement amounted to \$500.
- (iv) In August 2017, the Company issued 4,050,000, common shares of the Company at a price of \$0.05 per common share to settle \$202,500 of debt with certain management and suppliers of the Company.

Notes to Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2017 and 2016

12. Warrant Reserve

The movements in the number and estimated fair value of outstanding broker warrants and share purchase warrants are as follows:

	Nine months ended September 30, 2017		Year ended December 31, 2		
	Weighted Average Exercise		rage		
	Number Outstanding	Price \$	Number Outstanding	Price \$	
Balance, beginning of period	15,788,986	0.11	1,600,000	0.31	
Issued	2,475,760	0.07	14,388,986	0.10	
Expired	(1,400,000)	(0.25)	(200,000)	0.75	
Balance, end of period	16,864,746	0.10	15,788,986	0.11	

The exercise price, expiry date, and the fair value assigned to warrants issued and outstanding as at September 30, 2017 are as follows:

	Weighted Average	Fair		
	Exercise Price	Value	Warrants	Contractual
Expiry Date	\$	\$	Outstanding	Life (years)
June 8, 2018	0.10	10,400	650,000	0.69
June 23, 2018	0.10	14,000	875,000	0.73
August 14, 2018	0.10	123,200	7,700,000	0.87
September 28, 2018	0.10	43,100	3,913,986	1.00
December 19, 2018	0.10	26,600	1,250,000	1.22
January 20, 2019	0.10	9,045	425,000	1.31
February 22, 2019	0.10	6,385	300,000	1.40
April 21, 2018	0.10	350	84,000	0.56
August 14, 2022	0.05	10,170	333,500	4.87
August 17, 2022	0.05	63,530	1,333,260	4.88
	0.10	306,780	16,864,746	1.33

The fair values of the warrants issued during the year ended December 31, 2016 and nine months ended September 30, 2017 were estimated using the Black-Scholes option pricing model with the following weighted average assumptions:

	2017	2016
Risk free interest rate	0.72% -1.8%	0.57%
Expected dividend yield	Nil	Nil
Expected volatility	78% - 176%	187%
Expected life	1 to 5 years	2 years

Notes to Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2017 and 2016

Option pricing models require the input of subjective assumptions regarding the expected volatility. Changes in assumptions can materially affect the estimate of fair value, and therefore, use of Black-Scholes option pricing model may not provide a realistic measure of the fair value of the Company's warrants at the date of issue.

13. Stock Options

The Company has a stock option plan (the "Plan"), under which the Company may grant options to directors, officers, employees, and third party service providers. Under the terms of the Plan that was re-approved by the shareholders on July 3, 2013, the Company is authorized to issue a maximum of 10% of the issued and outstanding shares.

The purpose of the Plan is to attract, retain and motivate directors, officers, and certain third party service providers by providing them with the opportunity to acquire a proprietary interest in the Company and benefit from its growth. The options granted under the Plan are non-assignable, have a term of 5 years and vest over periods of up to two years from the date of issue.

	Nine months ended September 30, 2017		Year ende December 31,	
	Number Outstanding	Weighted Average Exercise Price \$	Number Outstanding	Weighted Average Exercise Price \$
Balance, beginning of period	3,070,000	0.14	230,000	1.00
Granted	300,000	0.07	2,850,000	0.07
Expired/Cancelled	(180,000)	1.00	(10,000)	1.00
Balance, end of period	3,190,000	0.08	3,070,000	0.14

Options to purchase common shares outstanding at September 30, 2017 carry exercise prices and remaining terms to maturity as follows:

Expiry Date	Weighted Average Exercise Price \$	Grant Date Fair Value \$	Number of Options Outstanding	Number of Options Exercisable	Weighted Average Contractual Life (years)
March 17, 2018	1.00	28,095	40,000	40,000	0.46
March 15, 2021	0.07	85,200	2,850,000	2,850,000	3.46
April 1, 2022	0.07	10,425	300,000	300,000	4.55
	0.08	123,720	3,190,000	3,190,000	3.09

During the nine months ended September 30, 2017, the Company granted 300,000 new options, During the year ended December 31, 2016, the Company granted 2,850,000 new options. The Company recognized a total expense of \$10,425 for the nine months ended September 30, 2017 and \$85,200 for the year ended December 31, 2016 in respect of the options vesting during the year. Share based payments expense is included in general and administrative costs.

Notes to Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2017 and 2016

The fair values of the options issued for the nine month ended September 30, 2017 and for the year ended December 31, 2016 were estimated using the Black-Scholes option pricing model with the following assumptions:

	2017	2016
Risk free interest rate	1.03%	0.89%
Expected dividend yield	Nil	Nil
Expected volatility	146%	156%
Expected life	5 years	5 years

14. Loss per Share

The calculation of basic and diluted loss per share for the nine months ended September 30, 2017 was based on the loss attributable to common shareholders of 1,057,145 (2016 - 600,251) and the weighted average number of common shares outstanding of 60,915,560 (2016 - 44,344,562). For the three months ended September 30, 2017, basic and diluted loss per share was based on the loss attributable to common shareholders of 332,500 (2016 - 209,123) and the weighted average number of common shares outstanding of 63,377,930 (2016 - 47,984,966). Diluted loss per share did not include the effect of share purchase options and warrants as they are anti-dilutive.

15. Operating and Administrative

Operating and administrative expense consists of the following:

	Three months ended September 30		Nine months ended September 30	
	2017	17 2016	2017	2016
	\$	\$	\$	\$
Salaries and management fees (note 8)	71,370	98,550	214,720	295,650
Share based payments (note 8)	10,425	-	10,425	62,700
Professional fees	52,536	56,064	185,561	113,977
Shareholder information and filing fees	44,822	33,377	144,430	72,759
Travel	10,370	6,497	28,125	7,850
General office expenses	2,927	5,425	13,357	17,205
Total	192,450	199,913	596,618	570,141

Notes to Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2017 and 2016

16. Finance Charges

Finance charges consist of the following:

	Three months ended September 30		Nine months ended September 30	
	2017	2016	2017	2016
	\$	\$	\$	\$
Interest and bank charges	1,215	1,085	8,495	2,205
Loan payable interest	5,977	8,125	19,427	28,175
Debenture interest	15,911	-	21,988	-
Accreation expense	10,730	-	12,610	-
Total	33,833	9,210	62,520	30,380

17. Financial Risk Factors

The Company's risk exposures and the impact on the Company's financial instruments are summarized below:

Credit risk

The Company has no significant concentration of credit risk arising from operations. Management believes that the credit risk concentration with respect to subscriptions receivable and sales tax receivable is remote.

Liquidity risk

As at September 30, 2017, the Company had a cash balance of \$34,895 (December 31, 2016 - \$1,103) to settle current liabilities of \$2,283,274 (December 31, 2016 - \$2,102,913). The Company does not have sufficient cash reserves to fund its administrative costs and fully fund all project development initiatives for the coming twelve month period, and to repay its liabilities to trade creditors and debt holders. Management is actively involved in identifying reclamation ventures amenable to the application of the Company's technology and in seeking new equity financing to enable it to service the Company's liabilities and its ongoing administrative costs. There can be no assurance that the Company will be successful in these initiatives.

Market risk

(a) Interest rate risk

The Company has cash earning interest at a variable interest rate, a loan payable and debentures bearing interest at 12% per annum. The Company's current policy is to invest excess cash in investment-grade short-term deposit certificates issued by its banking institutions.

(b) Foreign currency risk

The Company's functional currency is the Canadian dollar. Major purchases are transacted in Canadian dollars. The Company funds certain operations and administrative expenses using United States dollars. Management believes the foreign exchange risk derived from currency conversions is negligible and therefore does not hedge its foreign exchange risk.

Notes to Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2017 and 2016

(c) Price risk

The Company is not exposed to price risk with respect to commodity prices because the Company is not a producing entity.

18. Capital Management

The Company defines capital as share capital, warrant reserve, and option reserve. The Company's objective when managing capital is to safeguard its accumulated capital in order to provide an adequate return to shareholders by maintaining a sufficient level of funds, in order to support the acquisition, assessment and evaluation, and development of mineral reclamation properties. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business.

The Company is currently in the early stages of evaluation and assessment of projects; as such, the Company is dependent on external financing to fund its activities. In order to carry out the assessment and evaluation of the projects and pay for administrative costs, the Company will spend its existing working capital and raise additional amounts as needed. The Company will continue to assess new properties and seek to acquire an interest in additional properties, if it feels there is sufficient geologic or economic potential, and if it has adequate financial resources to do so.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. The Company does not have externally imposed capital requirements.

The Company's capital management objectives, policies and processes have remained unchanged during the nine months ended September 30, 2017 and year ended December 31, 2016.

The Company is not subject to any capital requirements imposed by a lending institution or regulatory body, other than of the Canadian Securities Exchange ("CSE"). The impact of any violation of CSE is not known and is ultimately dependent on the discretion of the CSE.

19. Commitments and Contingencies

Management contract

The Company currently has an employment agreement with the provision of termination and change of control benefits with an officer of the Company. The agreement for the officer provides that in the event that their employment is terminated by the Company other than for cause then the officer shall be entitled to a lump sum payment amount equal to 12 months base salary plus 1 month salary for each year of service from December 2, 2010, to a max of 36 months base salary. If a change of control were to occur, the officer would be entitled to 2 years of compensation (salary plus bonus), or the equivalent of \$450,000. As a triggering event has not taken place, the contingent payments have not been reflected in these condensed interim consolidated financial statements.

Environmental matters

The Company's exploration activities are subject to various laws and regulations governing the protection of the environment. These laws and regulations are continually changing and generally becoming more restrictive. The Company conducts its operations so as to protect public health and the environment and believes its operations are materially in compliance with all applicable laws and regulations. The Company has made, and expects to make in the future, expenditures to comply with such laws and regulations.

Notes to Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2017 and 2016

20. Bolivia project

On May 24, 2016, BacTech announced that its 98% owned Bolivian subsidiary Empresa Minera Ambiental BacTech S.A. ("EMABSA"), had signed an Association Contract with Corporación Minera de Bolivia ("COMIBOL"), the state mining company of Bolivia. On September 15, 2016, the Bolivian government approved and ratified the agreement.

The ten-year contract calls for the environmental remediation and restoration of the "Antigua" tailings and an option on the "Nuevo" tailings, both situated at the Telamayu mill site. Telamayu is situated near the town of Atocha in the Department of Potosi. The agreement envisions three phases, with the first phase focused on the completion of a technical study on the Antigua tails. Included in the study will be the drilling of a grid of 10 metre holes, that will provide information for a NI 43-101 study. In addition, tailings material will be used in metallurgical studies to determine the optimal flow chart for the proposed plant.

The Company is obligated to carry out an investigation of building a processing plant at Telamayu. Phase one is the completion of drilling, assay and metallurgical work to confirm economic viability of the project. To complete this the Company was required to put up a performance bond of \$32,000, which is included in prepaids. If the project is deemed viable, the Company will continue its work and will be subject to additional performance bonds.

The majority of the project expenditures have been incurred on the Bolivia Project which includes the drilling costs, assay work, NI 43-101 mineral resource estimate, management and consulting fees.

21. Subsequent event

Debenture with Net Smelter Return

On November 8, 2017, the Company announced that it will seek to raise up to \$500,000 through a non-brokered private placement in the form of a unique debenture offering open only to accredited investors (the "New Debentures").

The 2-year New Debenture will carry a 12% interest rate with interest to be paid annually, 1,333,333 warrants per \$100,000 debenture investment exercisable at a price of 7.5 cents per warrant entitling the holder to one common share of BacTech and will expire three (3) years from closing; in addition, the New Debenture will be accompanied by a Net Smelter Royalty ("NSR") of 2.5% to be paid annually from the cash flow generated at the Company's Telamayu tailings project (the "Telamayu Project") in Potosi State, Bolivia.